Libtayo (cemiplimab) is an antibody pharmaceutical. Cemiplimab was first approved as Libtayo on 2018-09-28. It is used to treat squamous cell carcinoma in the USA. It has been approved in Europe to treat squamous cell carcinoma. The pharmaceutical is active against programmed cell death protein 1.
|Indication||squamous cell carcinoma|
|Drug Class||Monoclonal antibodies: immunomodulating|